Research · Sep 3, 2026
[TMO] Thermo Fisher Thesis 2026: Biopharma End-Market Recovery + Olink Proteomics Test Platform Re-Acceleration
Thermo Fisher FY2025 revenue ~$43.5B (+3-5% YoY) with adj. operating margin ~22.5% — third year navigating COVID revenue wind-down ($7B FY2021 peak → $1B FY2025) while underlying biopharma services + life sciences tools recover. Laboratory Products & Biopharma Services ~$22B (largest segment) — integrated PPD CRO + Patheon CDMO + Fisher Scientific platform serves biopharmaceutical customers end-to-end. FY2026 thesis: biopharma capex/clinical trial spending re-accelerates on GLP-1 expansion + gene therapy commercialization + biosimilar launches; Olink (proteomics, $3.1B acquisition Aug 2024) scales as proteomics adoption accelerates; PPD margin expansion through synergy capture; key risks: biopharma funding constraint extends, China research market deterioration, NIH budget pressures.